Cargando…

Firmicutes and Blautia in gut microbiota lessened in chronic liver diseases and hepatocellular carcinoma patients: a pilot study

The gut microbiota system plays a vital role in liver diseases. This study aimed to address the diversity of gut microbiota and its correlations with clinical parameters in healthy individuals, chronic liver disease (CLD), and hepatocellular carcinoma (HCC) patients. Fecal specimens of nine healthy...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Tianyou, Ding, Rongrong, Chen, Xiaorong, Lu, Yunfei, Shi, Jia, Lü, Ying, Tang, Bozong, Zhang, Wensi, Ye, Chen, Yuan, Min, Yang, Zongguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806631/
https://www.ncbi.nlm.nih.gov/pubmed/34592890
http://dx.doi.org/10.1080/21655979.2021.1982273
_version_ 1784643496478507008
author Chen, Tianyou
Ding, Rongrong
Chen, Xiaorong
Lu, Yunfei
Shi, Jia
Lü, Ying
Tang, Bozong
Zhang, Wensi
Ye, Chen
Yuan, Min
Yang, Zongguo
author_facet Chen, Tianyou
Ding, Rongrong
Chen, Xiaorong
Lu, Yunfei
Shi, Jia
Lü, Ying
Tang, Bozong
Zhang, Wensi
Ye, Chen
Yuan, Min
Yang, Zongguo
author_sort Chen, Tianyou
collection PubMed
description The gut microbiota system plays a vital role in liver diseases. This study aimed to address the diversity of gut microbiota and its correlations with clinical parameters in healthy individuals, chronic liver disease (CLD), and hepatocellular carcinoma (HCC) patients. Fecal specimens of nine healthy individuals, 11 CLD, and 21 HCC were collected. The diversity of gut microbiota was examined by PCR and Illumina MiSeq sequencing and analyzed using 16S rRNA gene sequencing database. The correlations between gut microbiota and the clinical parameters of participants were also addressed. Compared to healthy individuals, Firmicutes at a phylum level decreased in CLD and HCC patients and Proteobacteria increased (p < 0.05). The composition of Blautia on a genus level in CLD and HCC patients significantly decreased compared to healthy controls (p < 0.05). Firmicutes composition was negatively associated with age and number of males (p < 0.05) and was positively associated with monocytes, high-density lipoprotein cholesterol (HDL-C), and estimated glomerular filtration rate (eGFR) levels (p < 0.05). At a genus level, Blautia composition was negatively associated with cirrhosis, age, and number of males (p < 0.01), while it was positively associated with red blood cells (RBCs), triglycerides, HDL-C, and lymphocyte levels (p < 0.05). Conclusively, there was a significant compositional difference in gut microbiota in CLD and HCC patients compared with healthy subjects. Firmicutes and Blautia in gut microbiota system lessened in CLD and HCC patients. Clinical biochemical parameters have an impact on the diversity of gut microbiota in liver diseases.
format Online
Article
Text
id pubmed-8806631
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-88066312022-02-02 Firmicutes and Blautia in gut microbiota lessened in chronic liver diseases and hepatocellular carcinoma patients: a pilot study Chen, Tianyou Ding, Rongrong Chen, Xiaorong Lu, Yunfei Shi, Jia Lü, Ying Tang, Bozong Zhang, Wensi Ye, Chen Yuan, Min Yang, Zongguo Bioengineered Research Paper The gut microbiota system plays a vital role in liver diseases. This study aimed to address the diversity of gut microbiota and its correlations with clinical parameters in healthy individuals, chronic liver disease (CLD), and hepatocellular carcinoma (HCC) patients. Fecal specimens of nine healthy individuals, 11 CLD, and 21 HCC were collected. The diversity of gut microbiota was examined by PCR and Illumina MiSeq sequencing and analyzed using 16S rRNA gene sequencing database. The correlations between gut microbiota and the clinical parameters of participants were also addressed. Compared to healthy individuals, Firmicutes at a phylum level decreased in CLD and HCC patients and Proteobacteria increased (p < 0.05). The composition of Blautia on a genus level in CLD and HCC patients significantly decreased compared to healthy controls (p < 0.05). Firmicutes composition was negatively associated with age and number of males (p < 0.05) and was positively associated with monocytes, high-density lipoprotein cholesterol (HDL-C), and estimated glomerular filtration rate (eGFR) levels (p < 0.05). At a genus level, Blautia composition was negatively associated with cirrhosis, age, and number of males (p < 0.01), while it was positively associated with red blood cells (RBCs), triglycerides, HDL-C, and lymphocyte levels (p < 0.05). Conclusively, there was a significant compositional difference in gut microbiota in CLD and HCC patients compared with healthy subjects. Firmicutes and Blautia in gut microbiota system lessened in CLD and HCC patients. Clinical biochemical parameters have an impact on the diversity of gut microbiota in liver diseases. Taylor & Francis 2021-10-19 /pmc/articles/PMC8806631/ /pubmed/34592890 http://dx.doi.org/10.1080/21655979.2021.1982273 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Chen, Tianyou
Ding, Rongrong
Chen, Xiaorong
Lu, Yunfei
Shi, Jia
Lü, Ying
Tang, Bozong
Zhang, Wensi
Ye, Chen
Yuan, Min
Yang, Zongguo
Firmicutes and Blautia in gut microbiota lessened in chronic liver diseases and hepatocellular carcinoma patients: a pilot study
title Firmicutes and Blautia in gut microbiota lessened in chronic liver diseases and hepatocellular carcinoma patients: a pilot study
title_full Firmicutes and Blautia in gut microbiota lessened in chronic liver diseases and hepatocellular carcinoma patients: a pilot study
title_fullStr Firmicutes and Blautia in gut microbiota lessened in chronic liver diseases and hepatocellular carcinoma patients: a pilot study
title_full_unstemmed Firmicutes and Blautia in gut microbiota lessened in chronic liver diseases and hepatocellular carcinoma patients: a pilot study
title_short Firmicutes and Blautia in gut microbiota lessened in chronic liver diseases and hepatocellular carcinoma patients: a pilot study
title_sort firmicutes and blautia in gut microbiota lessened in chronic liver diseases and hepatocellular carcinoma patients: a pilot study
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806631/
https://www.ncbi.nlm.nih.gov/pubmed/34592890
http://dx.doi.org/10.1080/21655979.2021.1982273
work_keys_str_mv AT chentianyou firmicutesandblautiaingutmicrobiotalessenedinchronicliverdiseasesandhepatocellularcarcinomapatientsapilotstudy
AT dingrongrong firmicutesandblautiaingutmicrobiotalessenedinchronicliverdiseasesandhepatocellularcarcinomapatientsapilotstudy
AT chenxiaorong firmicutesandblautiaingutmicrobiotalessenedinchronicliverdiseasesandhepatocellularcarcinomapatientsapilotstudy
AT luyunfei firmicutesandblautiaingutmicrobiotalessenedinchronicliverdiseasesandhepatocellularcarcinomapatientsapilotstudy
AT shijia firmicutesandblautiaingutmicrobiotalessenedinchronicliverdiseasesandhepatocellularcarcinomapatientsapilotstudy
AT luying firmicutesandblautiaingutmicrobiotalessenedinchronicliverdiseasesandhepatocellularcarcinomapatientsapilotstudy
AT tangbozong firmicutesandblautiaingutmicrobiotalessenedinchronicliverdiseasesandhepatocellularcarcinomapatientsapilotstudy
AT zhangwensi firmicutesandblautiaingutmicrobiotalessenedinchronicliverdiseasesandhepatocellularcarcinomapatientsapilotstudy
AT yechen firmicutesandblautiaingutmicrobiotalessenedinchronicliverdiseasesandhepatocellularcarcinomapatientsapilotstudy
AT yuanmin firmicutesandblautiaingutmicrobiotalessenedinchronicliverdiseasesandhepatocellularcarcinomapatientsapilotstudy
AT yangzongguo firmicutesandblautiaingutmicrobiotalessenedinchronicliverdiseasesandhepatocellularcarcinomapatientsapilotstudy